Brief: BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
02/12/2024 12:59
Dec 2 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL RECEIVES GREEN-LIGHT FROM DATA SAFETY MONITORING
BOARD
FOR ITS PHASE 3 STUDY IN METASTATIC BREAST CANCER
Source text: ID:nGNX1HzTqK
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study